CD8A and neoplasm: The brief treatment of the majority of patients suggest DeltaRex-G may have longer term benefits that could complement immunotherapy since histopathologic examination of a biopsied residual tumor showed presence of CD8+ killer cells and CD45+ immune cells in the tumor microenvironment (Figure 3).